Translate
Immuneering Corp
About
Immuneering Corp (NASDAQ:IMRX) — investor relations, events, news, and company updates on 6ix.
Latest News
Apr 21 2026
Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting
Apr 20 2026
Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond
Mar 17 2026
Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival
Mar 6 2026
Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Mar 2 2026
Immuneering to Present at the Leerink Global Healthcare Conference
Recent Videos
How Immuneering’s Journey Highlights the Biotech's Market Complexity, with CEO Ben Zeskind
Mar 20, 2026
Cómo invertir en Immuneering Corporation (IMRX)
Mar 14, 2026
IMRX STOCK : PRICE RECOVERY | IMMUNEERING STOCK
Feb 06, 2026
Is Immuneering Corp IMRX A Good Time To Buy Now? IMRX Stock Analysis
Jan 25, 2026
Financials
Revenue
$455
Market Cap
$352.36 M
EPS
-1.27